Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia

2 november 2026 bijgewerkt door: LAI KWAN LAM, Chinese University of Hong Kong

Enhancing Cardiometabolic Health in Postnatal Women at High-Risk for Preeclampsia Through Exercise Intervention

Women who develop hypertensive disorders of pregnancy have an increased risk of cardiovascular disease later in life. Whether exercise during the postpartum period improves cardiometabolic health in this population remains unclear.

This pilot randomized controlled trial will recruit 40 women who were identified as being at high risk for preeclampsia during pregnancy and subsequently developed a hypertensive disorder of pregnancy. Participants will be enrolled 6 to 8 weeks after delivery and randomly assigned to a 12-week exercise program or standard postnatal care. The exercise program will consist of three sessions per week combining moderate-intensity aerobic exercise, resistance training, and pelvic floor exercises.

Cardiovascular function, blood pressure, blood markers of cardiometabolic health, physical fitness, and body composition will be assessed before and after the 12-week period. Changes in mood, sleep quality, and health-related quality of life will also be evaluated. The study will provide preliminary evidence on the effects of postpartum exercise in this population and inform the design of a larger trial.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

40

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Hongkong
    • Hong Kong
      • Hong Kong, Hong Kong, Hongkong
        • Werving
        • Department of Obstetrics & Gynaecology, Prince of Wales Hospital
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 45 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Aged 18 to 45 years.
  • Identified as being at high risk for preeclampsia during the most recent pregnancy and developed a hypertensive disorder of pregnancy (HDP).
  • Had a singleton pregnancy.
  • 6 to 8 weeks postpartum at enrollment.
  • Physically able to participate in the exercise training program.
  • Willing to participate in the study and provide informed consent.

Exclusion Criteria:

  • Had a multiple pregnancy.
  • Severe medical complications after delivery or other health conditions that contraindicate physical exercise (e.g., severe cardiovascular disease or musculoskeletal disorders).
  • Chronic hypertension or diabetes before pregnancy.
  • Current use of medication that could potentially affect cardiac function (e.g., medication for heart failure).
  • Received antibiotic treatment within the past month.
  • Severe mental health disorders that affect the ability to exercise.
  • Unable or unwilling to adhere to and attend the 12-week exercise program.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Postpartum Exercise Program

Participants will complete a 12-week exercise program consisting of three supervised sessions per week. Each session will combine moderate-intensity aerobic exercise, resistance training, and pelvic floor exercises. Exercise intensity will be adjusted to individual fitness levels and monitored using heart rate and ratings of perceived exertion.
Gedragsmatig: Postpartum Exercise Program

Participants assigned to the exercise group will undertake a 12-week program comprising three supervised 60-minute sessions per week. Each session includes a 5-minute warm-up, 20 minutes of moderate-intensity aerobic exercise on a treadmill or stationary bicycle, 20 minutes of resistance training, 10 minutes of pelvic floor exercises, and a 5-minute cool-down. Exercise intensity will be individualized and progressively adjusted according to heart rate and rating of perceived exertion.
Geen tussenkomst: Standard Postnatal Care

Participants will receive standard postnatal care, including routine health check-ups and general advice on postnatal health. They will not receive a structured exercise program as part of the study.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Systolic Blood Pressure
Tijdsspanne: Before and after the 12-week exercise intervention

Systolic blood pressure will be measured in mmHg. Change from baseline to the end of the 12-week intervention will be assessed.
Before and after the 12-week exercise intervention
Change in Diastolic Blood Pressure
Tijdsspanne: Baseline and 12 weeks

Diastolic blood pressure will be measured in mmHg using a validated automated device. Change from baseline to the post-intervention assessment will be assessed.
Baseline and 12 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Triglyceride Levels
Tijdsspanne: Baseline and 12 weeks

Serum triglyceride levels will be determined using standard laboratory techniques. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Total Cholesterol Levels
Tijdsspanne: Baseline and 12 weeks

Serum total cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed.
Baseline and 12 weeks
Change in High-Density Lipoprotein Cholesterol Levels
Tijdsspanne: Baseline and 12 weeks

Serum high-density lipoprotein cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Low-Density Lipoprotein Cholesterol Levels
Tijdsspanne: Baseline and 12 weeks

Serum low-density lipoprotein cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Apolipoprotein A-I Levels
Tijdsspanne: Baseline and 12 weeks

Apolipoprotein A-I levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Apolipoprotein A-II Levels
Tijdsspanne: Baseline and 12 weeks

Apolipoprotein A-II levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Apolipoprotein B Levels
Tijdsspanne: Baseline and 12 weeks

Apolipoprotein B levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Fasting Glucose Levels
Tijdsspanne: Baseline and 12 weeks

Fasting glucose levels will be determined using standard laboratory tests. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Glycated Hemoglobin (HbA1c)
Tijdsspanne: Baseline and 12 weeks

HbA1c will be determined using standard laboratory tests. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Fasting Insulin Levels
Tijdsspanne: Baseline and 12 weeks

Fasting insulin levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in C-Peptide Levels
Tijdsspanne: Baseline and 12 weeks

C-peptide levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Adiponectin Levels
Tijdsspanne: Baseline and 12 weeks

Adiponectin levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Leptin Levels
Tijdsspanne: Baseline and 12 weeks

Leptin levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in High-Sensitivity C-Reactive Protein Levels
Tijdsspanne: Baseline and 12 weeks

High-sensitivity C-reactive protein levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Tumor Necrosis Factor-Alpha Levels
Tijdsspanne: Baseline and 12 weeks

Tumor necrosis factor-alpha levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Interleukin-6 Levels
Tijdsspanne: Baseline and 12 weeks

Interleukin-6 Levels Interleukin-6 levels will be measured using ELISA. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Fibrinogen Levels
Tijdsspanne: Baseline and 12 weeks

Blood fibrinogen levels will be measured using a commercial ELISA kit. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Endothelin-1 Levels
Tijdsspanne: Baseline and 12 weeks

Endothelin-1 Levels Endothelin-1 levels will be measured using a commercial ELISA kit. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Angiotensin II Levels
Tijdsspanne: Baseline and 12 weeks

Angiotensin II levels will be measured using a commercial ELISA kit. Changes in levels will be assessed.
Baseline and 12 weeks
Change in Edinburgh Postnatal Depression Scale Score
Tijdsspanne: Baseline and 12 weeks

Postpartum depressive symptoms will be assessed using the Edinburgh Postnatal Depression Scale (EPDS). Change in score from before to after the 12-week intervention will be assessed.
Baseline and 12 weeks
Change in 36-Item Short Form Health Survey Scores
Tijdsspanne: Baseline and 12 weeks

Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). Changes in questionnaire scores from before to after the 12-week intervention will be assessed.
Baseline and 12 weeks
Change in Pittsburgh Sleep Quality Index Score
Tijdsspanne: Baseline and 12 weeks

Pittsburgh Sleep Quality Index Score Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Change in score from before to after the 12-week intervention will be assessed.
Baseline and 12 weeks
Change in Breastfeeding Self-Efficacy Scale-Short Form Score
Tijdsspanne: Baseline and 12 weeks

Breastfeeding self-efficacy will be assessed using the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF). Change in score from before to after the 12-week intervention will be assessed.
Baseline and 12 weeks
Change in Six-Minute Walk Test Performance
Tijdsspanne: Baseline and 12 weeks

Physical performance will be assessed using the Six-Minute Walk Test. Change from baseline to the post-intervention assessment will be assessed.
Baseline and 12 weeks
Change in Chair Stand Test Performance
Tijdsspanne: Baseline and 12 weeks

Lower-body physical performance will be assessed using a Chair Stand test. Change from baseline to the post-intervention assessment will be assessed.
Baseline and 12 weeks
Change in Body Mass Index
Tijdsspanne: Baseline and 12 weeks

Body mass index (BMI) will be measured. Change from baseline to the post-intervention assessment will be assessed.
Baseline and 12 weeks
Change in Fat Mass Percentage
Tijdsspanne: Baseline and 12 weeks

Body fat percentage will be assessed at baseline and after the intervention. Changes from baseline to the post-intervention assessment will be evaluated.
Baseline and 12 weeks
Change in Lean Mass Percentage
Tijdsspanne: Baseline and 12 weeks

Lean mass percentage will be assessed at baseline and after the intervention. The change from baseline to the post-intervention assessment will be evaluated.
Baseline and 12 weeks
Change in Vital Capacity
Tijdsspanne: Baseline and 12 weeks

Change in vital capacity from baseline to the post-intervention assessment will be assessed.
Baseline and 12 weeks
Change in Plank Test Performance
Tijdsspanne: Baseline and 12 weeks

Change in plank test performance from baseline to the post-intervention assessment will be assessed.
Baseline and 12 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Chinese University of Hong Kong

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 september 2026

Primaire voltooiing (Geschat)

30 september 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

2 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

2 november 2026

Eerst geplaatst (Werkelijk)

6 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • CREC Ref. No.: 2024.459

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren